Prospect Of CAR-NK Cell In Tumor Immunotherapy

Authors

  • Yanyu Jiang

DOI:

https://doi.org/10.54097/radssw50

Keywords:

Natural killer (NK) cells, CAR-T cell therapy, CAR-NK cell therapy.

Abstract

The innate immune system has gained significant interest expected to the impressive natural killer (NK) cells ability to surveil and combat pathogens, regardless of major histocompatibility complex. Following the resounding success of CAR-T cell therapy, there has been a burgeoning interest in harnessing the NK therapeutics potential in recent years. Owing to its clinical triumphs, which those achieved by CAR-T cell therapy, this subject has garnered a discernible level of fascination. A captivating realm of investigation within tumor immunotherapy lies in delving into chimeric antigen receptor (CAR) engineering applied to. In the wake of the astounding achievements witnessed with CAR-T cell therapy for CD19 hematologic disorders, CAR-NK cells are emerging as an auspicious adjunctive strategy to cellular therapy following CAR-T cells. It is intriguing that CAR-NK cells exhibit comparable efficacy against malignancies as demonstrated in CAR-T cell therapy, and preliminary clinical investigations have yielded promising outcomes. review aims to furnish a meticulous synopsis of the advancements in CAR-NK cell treatment, encompassing methodologies for generating and genetically manipulating CAR-NK cells. Additionally, it examines the obstacles and future possibilities associated with utilizing CAR-NK as an advanced form of immunotherapy against cancer. The primary aim of this prospective study is clarify reasons behind implementing CAR-NK as a novel approach to anticancer immunotherapy.

Downloads

Download data is not yet available.

References

Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018). Natural killer cells and other innate lymphoid cells in cancer. Nature Reviews Immunology, 18(11), 671–688.

Du, N., Guo, F., Wang, Y., & Cui, J. (2021). NK Cell Therapy: A Rising Star in Cancer Treatment. Cancers, 13(16), 4129.

Li, L., Chen, H., Marin, D., Xi, Y., Miao, Q., Lv, J., Banerjee, P. P., Shaim, H., Daher, M., Basar, R., Imahashi, N., Jimenez, J., Hu, B., Mehta, R. S., Kerbauy, L. N., Kaplan, M., Mendt, M., Ozcan, G., Gokdemir, E., & Hernandez Sanabria, M. (2019). A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Advances, 3(23), 4117–4130.

Kundu, S., Gurney, M., & O’Dwyer, M. (2021). Generating natural killer cells for adoptive transfer: expanding horizons. Cytotherapy, 23(7), 559–566.

Lanier, L. L. (1998). NK CELL RECEPTORS. Annual Review of Immunology, 16(1), 359–393.

Bald, T., Krummel, M. F., Smyth, M. J., & Barry, K. C. (2020). The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. Nature Immunology, 21(8), 835–847.

Kandel, E. S., Skeen, J., Majewski, N., Di Cristofano, A., Pandolfi, P. P., Feliciano, C. S., Gartel, A., & Hay, N. (2002). Activation of Akt/Protein Kinase B Overcomes a G2/M Cell Cycle Checkpoint Induced by DNA Damage. Molecular and Cellular Biology, 22(22), 7831–7841.

Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022). Natural killer cells in antitumour adoptive cell immunotherapy. Nature Reviews Cancer.

Daher, M., Melo Garcia, L., Li, Y., & Rezvani, K. (2021). CAR‐NK cells: the next wave of cellular therapy for cancer. Clinical & Translational Immunology, 10(4), e1274.

Pfefferle, A., & Huntington, N. D. (2020). You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy. Cancers, 12(3), 706.

Kotch, C., Barrett, D., & Teachey, D. T. (2019). Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Review of Clinical Immunology, 15(8), 813–822.

Voynova, E., Hawk, N., Flomerfelt, F. A., Telford, W. G., Gress, R. E., Kanakry, J. A., & Kovalovsky, D. (2022). Increased Activity of a NK-Specific CAR-NK Framework Targeting CD3 and CD5 for T-Cell Leukemias. Cancers, 14(3), 524.

Downloads

Published

29-12-2023